| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
|
Circulation
|
1998
|
1.93
|
|
2
|
Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm.
|
Am J Cardiol
|
1988
|
1.81
|
|
3
|
Exercise training combined with antihypertensive drug therapy. Effects on lipids, blood pressure, and left ventricular mass.
|
JAMA
|
1990
|
1.54
|
|
4
|
Effects of diltiazem or propranolol during exercise training of hypertensive men.
|
Med Sci Sports Exerc
|
1990
|
1.41
|
|
5
|
Abciximab readministration: results of the ReoPro Readministration Registry.
|
Circulation
|
2001
|
1.01
|
|
6
|
Changes in myosin isoenzymes, ATPase activity, and contraction duration in rat cardiac muscle with aging can be modulated by thyroxine.
|
Circ Res
|
1987
|
0.94
|
|
7
|
Elastic properties of the human chest during cardiopulmonary resuscitation.
|
Crit Care Med
|
1983
|
0.93
|
|
8
|
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial.
|
Am J Cardiol
|
1999
|
0.85
|
|
9
|
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
|
Ann Thorac Surg
|
2000
|
0.84
|
|
10
|
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
|
Circulation
|
1996
|
0.82
|
|
11
|
Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.
|
Drugs Aging
|
2000
|
0.81
|
|
12
|
Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study.
|
Catheter Cardiovasc Interv
|
1999
|
0.79
|
|
13
|
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
|
Int J Geriatr Psychiatry
|
2001
|
0.78
|
|
14
|
Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.
|
Circulation
|
2000
|
0.77
|
|
15
|
Readministration of abciximab: interim report of the ReoPro readministration registry.
|
Am Heart J
|
1999
|
0.77
|
|
16
|
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
|
Thromb Haemost
|
2014
|
0.76
|
|
17
|
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
|
Am Heart J
|
2000
|
0.76
|
|
18
|
The use of a low-level stage during exercise testing in predicting severe coronary disease.
|
Md Med J
|
1991
|
0.75
|
|
19
|
Hemodynamic vascular forces contribute to impaired endothelium-dependent vasodilation in reperfused canine epicardial coronary arteries.
|
J Am Coll Cardiol
|
1994
|
0.75
|
|
20
|
Effect of tris(hydroxymethyl)aminomethane on ischemic myocardium.
|
Am J Physiol
|
1978
|
0.75
|